Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) constitutes a progressive, debilitating disease of increasing prevalence that causes substantial morbidity and mortality worldwide \[[@C1]\]. Albeit its diagnostic and therapeutic management are primarily guided by the severity of airflow limitation, the complexity of the disease course is importantly influenced by its extrapulmonary comorbid manifestations \[[@C2]--[@C4]\]. It is noteworthy that comorbidities considerably affect outcomes in COPD, with cardiovascular diseases constituting a major cause of death \[[@C5]\]. In COPD as a multicomponent disorder, the inflammatory response that results from exposure to noxious environmental fumes becomes noticeable at both the local and systemic level \[[@C6]\]. Atherosclerotic conditions may arise as a consequence of common risk factors, primarily tobacco smoke, and of a systemic pro-inflammatory state. As such, the onset and progress of peripheral artery disease is markedly influenced by vascular inflammatory processes \[[@C7]\]. Although numerous inflammatory variables have been identified to play a major role in both peripheral artery disease and COPD, interdependence and coexistence of both disease entities are conceivable but still undefined. In a study cohort comprising 30 patients with advanced peripheral artery disease, W[ozniak]{.smallcaps} *et al*. \[[@C8]\] spirometrically ascertained concomitant COPD to be present in 46.7% of patients. This observation hints at a mutual association and raises the question whether COPD *vice versa* impacts peripheral artery disease occurrence and progression. In keeping with this, we conducted this prospective, cross-sectional study to investigate the frequency of lower extremity artery disease (LEAD) and carotid artery disease in COPD patients and current or former control smokers, and related angiological results to severity of obstructive airflow limitation.

Materials and methods {#s2}
=====================

Patient population {#s2a}
------------------

Between June 2014 and December 2015, a total of 107 patients aged ≥18 years receiving treatment at the Dept of Pneumology, University Hospital Bonn (Bonn, Germany) for spirometrically and clinically confirmed COPD participated in this prospectively conducted study. All patients received outpatient care; none were locally hospitalised. Exclusion criteria for study participation comprised previously diagnosed LEAD and carotid artery disease (including cerebrovascular disorders) as well as acute exacerbated COPD at the time of evaluation. All patients underwent angiological examination and complementary laboratory testing. Comorbidities, established risk factors for cardiovascular disorders, smoking history and current medication use were assessed by standardised questionnaire and appraisal of medical reports (physician\'s letters, laboratory values, list of medication).

The control cohort consisted of ex-smokers or current smokers who were recruited from the general population by screening invitation and in whom no COPD or atherosclerotic disorder had been diagnosed beforehand. Potential controls underwent pulmonary function testing to confirm absence of COPD. 22 controls were matched against COPD patients for age, gender, smoking habits and frequency of concomitant cardiovascular risk factors, and likewise underwent the aforementioned diagnostics.

The study was approved by the Ethics Committee of the University of Bonn and complied with the Declaration of Helsinki. All patients gave their written informed consent prior to entry into the study.

Pulmonary function testing {#s2b}
--------------------------

In conformity with the current guidelines \[[@C1]\], classification of COPD severity was performed by post-bronchodilator spirometry assessment of airflow limitation, symptomatic evaluation using the validated COPD Assessment Test and appraisal of exacerbation history. Concurrently, body plethysmography, diffusion capacity testing for carbon monoxide and capillary blood gas analysis permitted quantification of hyperinflation, ventilation and oxygenation status.

Laboratory testing {#s2c}
------------------

All study participants underwent blood sampling that encompassed a complete blood cell count and high-sensitivity C-reactive protein (hs-CRP).

Angiological screening {#s2d}
----------------------

Angiological testing comprised examination for both LEAD and carotid artery disease, and was performed by experienced angiologists, blinded to all clinical data, in line with the current European Society of Cardiology (ESC) guidelines \[[@C9]\]. For evaluation of carotid artery disease and quantification of its severity, colour-coded duplex ultrasonography was employed, according to the revised DEGUM (Ultraschall-Akademie der Deutschen Gesellschaft für Ultraschall in der Medizin) ultrasound criteria \[[@C10]\].

Noninvasive vascular testing for LEAD included ankle--brachial index (ABI) measurement, colour-coded duplex sonography as well as assessment of central pulse wave velocity (cPWV) and pulse wave index (PWI). Clinical LEAD categorisation accorded with Fontaine classification, and was ascertained by the treadmill test and anamnestic specification. Consistent with the current ESC guidelines on peripheral artery disease \[[@C9]\], ABI was calculated by Doppler-guided measurement of each foot\'s dorsalis pedis and posterior tibial arteries systolic pressure and its division by the systolic brachial pressure. Mean ABI, obtained by averaging the resulting four ABI values, was employed for statistical analysis. An ABI \<0.9 indicated occlusive arterial disease. Complementary colour-coded duplex ultrasonography provided additional information as it allowed for visualisation of the vascular lesion\'s extent and severity, and consequently of the atherosclerotic plaque burden. As one of the major indicators for arterial stiffness, brachial--ankle cPWV was assessed \[[@C11]\]. PWI measurement permitted ascertainment of subclinical LEAD stages even in the absence of ABI alterations; a PWI \>180 was considered pathological \[[@C12]\]. cPWV and PWI assessments were performed by use of an AngE Pro8 pulse oscillography device (Sonotechnik Austria, Maria Rain, Austria).

Statistical analysis {#s2e}
--------------------

Categorical data were presented as absolute number and percentages; continuous variables were expressed as mean±[sd]{.smallcaps} or median (interquartile range). Comparison of continuous variables was carried out by the *t*-test or univariate ANOVA. For categorical parameters, Fisher\'s exact test or Pearson\'s Chi-squared test was employed. Correlation was assessed by use of Pearson\'s correlation coefficient. In order to describe the influence potential confounders have on lower extremity plaque presence as a binary dependent variable, a logistic regression model was employed. All statistical analyses were performed with SPSS Statistics version 23.0 (IBM, Armonk, NY, USA).

Results {#s3}
=======

Characteristics of the study population {#s3a}
---------------------------------------

Demographic features and clinical data of study participants are displayed in [table 1](#TB1){ref-type="table"}. Intercohortal comparison was performed by defining controls as the COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 0 group.

###### 

Demographic and clinical characteristics of the study population

                                                               **All study participants**   **All COPD patients**   **COPD GOLD stage**   **Controls**   **p-value^\#^**   **p-value^¶^**                          
  ----------------------------------------------------------- ---------------------------- ----------------------- --------------------- -------------- ----------------- ---------------- ------------- --------- ---------
  **Subjects**                                                            129                        107                     6                 52               4                45             22                 
  **Demographics**                                                                                                                                                                                                 
   Age years                                                           64.0±10.1                  64.6±10.4              65.3±10.1         63.7±11.8        73.3±4.3          64.8±8.8       60.9±7.7      0.21      0.12
   Male                                                                70 (54.3)                  58 (52.2)              3 (50.0)          29 (55.8)        1 (25.0)         25 (55.6)       12 (54.5)     0.83      0.98
   BMI kg·m^−2^                                                         26.2±5.1                  25.9±5.3               26.8±6.0           26.3±4.8        23.6±3.5          25.5±5.9       27.6±4.0      0.55      0.18
  **Smoking history**                                                                                                                                                                                              
   Pack-years                                                         30 (0--150)                30 (0--150)           17.5 (2--40)       30 (0--125)      40 (20--60)      40 (0--150)     30 (5--150)    0.22      0.20
   Current smoker                                                      26 (20.2)                  22 (20.5)              1 (16.7)          13 (25.0)        2 (50.0)          6 (13.3)       4 (18.2)      0.69      0.35
   Ex-smoker                                                           98 (75.9)                  80 (74.8)              5 (83.3)          35 (67.3)        2 (50.0)         38 (84.4)       18 (81.8)     0.21      0.49
   Never-smoker                                                         5 (3.9)                    5 (4.7)                 0 (0)            4 (7.7)           0 (0)           1 (2.2)          0 (0)       0.46      0.31
   α~1~-Antitrypsin deficiency                                          6 (4.7)                    6 (5.6)               1 (16.7)           2 (3.8)         1 (25.0)          3 (6.7)          0 (0)       0.22      0.21
  **Cardiovascular risk factors**                                                                                                                                                                                  
   Arterial hypertension                                               60 (46.5)                  50 (46.7)              4 (66.7)          20 (38.5)        2 (50.0)         24 (53.3)       10 (45.5)     0.32      0.41
   Diabetes mellitus                                                   15 (11.6)                  13 (12.1)                0 (0)            6 (11.5)          0 (0)           7 (15.6)        2 (9.1)      0.57      0.50
   Dyslipidaemia^+^                                                    46 (35.7)                  39 (36.4)              2 (33.3)          19 (36.5)        2 (50.0)         16 (35.6)       7 (31.8)      0.44      0.33
   Obesity                                                             27 (20.9)                  23 (21.5)              1 (16.7)          13 (25.0)          0 (0)           9 (20.0)       4 (18.2)      0.69      0.44
   Familial disposition                                                37 (28.7)                  27 (25.2)              2 (33.3)          16 (30.8)          0 (0)           9 (20.0)       10 (45.5)     0.51      0.40
  **Comorbidities**                                                                                                                                                                                                
   Coronary heart disease                                              23 (17.8)                  23 (21.5)              3 (50.0)          12 (23.1)        1 (25.0)          7 (15.6)         0 (0)       0.002     0.004
   Pulmonary hypertension                                               10 (7.8)                  10 (9.3)                 0 (0)            5 (9.6)         1 (25.0)          4 (8.9)          0 (0)       0.25      0.06
  **Cardiovascular medication use**                                                                                                                                                                                
   Platelet inhibitor                                                  27 (20.9)                  27 (25.2)              3 (50.0)          13 (25.0)        2 (50.0)          9 (20.0)         0 (0)       0.02      0.001
   β-Blocker                                                           39 (30.2)                  39 (36.4)              1 (16.7)          21 (40.4)        3 (75.0)         14 (31.1)         0 (0)       0.007     0.003
   Statin                                                              25 (19.4)                  25 (23.4)              3 (50.0)          12 (23.1)        1 (25.0)          9 (20.0)         0 (0)       0.05      0.005
   Digitalis                                                            3 (2.3)                    3 (2.8)                 0 (0)            1 (1.9)           0 (0)           2 (4.4)          0 (0)       0.80      0.43
   Amiodarone                                                           2 (1.6)                    2 (1.9)                 0 (0)            1 (1.9)           0 (0)           1 (2.2)          0 (0)       0.96      0.52
  **Anti-obstructive and anti-inflammatory medication use**                                                                                                                                                        
   Long-acting β~2~-agonist                                            78 (60.5)                  78 (72.9)              1 (16.7)          36 (69.2)        3 (75.0)         38 (84.4)         0 (0)      \<0.001   \<0.001
   Long-acting anticholinergic                                         68 (52.7)                  68 (63.6)                0 (0)           29 (55.8)        1 (25.0)         38 (84.4)         0 (0)      \<0.001   \<0.001
   Inhaled glucocorticoid                                              46 (35.7)                  46 (43.0)                0 (0)             0 (0)          3 (75.0)         43 (95.6)         0 (0)      \<0.001   \<0.001
   Systemic glucocorticoid                                              7 (5.4)                    7 (6.5)                 0 (0)             0 (0)            0 (0)           7 (15.6)         0 (0)      \<0.001    0.05
   PDE-4 inhibitor  (roflumilast)                                      19 (14.7)                  19 (17.8)                0 (0)             0 (0)          1 (25.0)         18 (40.0)         0 (0)      \<0.001    0.02
  **Home oxygen therapy**                                              21 (16.3)                  21 (19.6)                0 (0)             0 (0)          2 (50.0)         19 (42.2)         0 (0)      \<0.001    0.003

Data are presented as n (%), mean±[sd]{.smallcaps} or median (range), unless otherwise stated. COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; BMI: body mass index; PDE-4: phosphodiesterase type 4. ^\#^: intercohortal comparison was performed by defining controls as the COPD GOLD 0 group, p-values refer to data comparison between all five groups (COPD GOLD 0 through D); ^¶^: p-values refer to data comparison between the entire COPD group and controls; ^+^: dyslipidaemia was defined on the basis of total cholesterol and low-density lipoprotein cholesterol levels \[13\].

Within the COPD cohort, 5.6%, 48.6%, 3.7% and 42.1% of patients were in COPD GOLD groups A, B, C and D, respectively. Pulmonary function testing revealed an overall forced expiratory volume in 1 s (FEV~1~)/forced vital capacity (FVC) ratio of 59.7±15.3% ([table 2](#TB2){ref-type="table"}). FEV~1~ accounted for 1.6±0.8 L in absolute terms and 56.7±21.8% of the predicted value. Prior or continued nicotine consumption was exhibited by 95.3% of patients (median 30 pack-years); six out of 107 patients were α~1~-antitrypsin deficient. Capillary blood gas analysis showed a resting oxygen and carbon dioxide tension of 66.2±12.6 and 36.2±6.8 mmHg, respectively. 19.6% of the COPD cohort was under long-term supplemental oxygen therapy. Bronchodilative and anti-inflammatory background medication in use at the time of study is given in [table 1](#TB1){ref-type="table"}; eight out of 107 COPD patients had previously undergone endoscopic lung volume reduction (three and five patients by endobronchial valve and coil placement, respectively). With regard to cardiovascular medication, the use of antiplatelet agents and β-blockers significantly differed between groups, and correlated with the presence of coronary heart disease (Pearson\'s r=0.48, p\<0.001 and Pearson\'s r=0.20, p=0.03, respectively). As for established cardiovascular risk factors, no significant distributive intercohortal differences were detected.

###### 

Pulmonary functional characterisation of the study population

                                       **All study participants**   **All COPD patients**   **COPD GOLD stage**   **Controls**   **p-value^\#^**   **p-value^¶^**                         
  ----------------------------------- ---------------------------- ----------------------- --------------------- -------------- ----------------- ---------------- ------------ --------- ---------
  **Subjects**                                    129                        107                     6                 52               4                45             22                
  **Pulmonary function parameters**                                                                                                                                                       
   FEV~1~ L^+^                                 1.80±0.93                  1.57±0.77              1.76±0.86         2.01±0.74        1.16±0.20        1.26±0.37      3.02±0.75    \<0.001   \<0.001
   FEV~1~ % pred^+^                            63.7±25.6                  56.7±21.8              70.3±15.0         70.6±14.2        48.1±2.5         45.2±14.1      98.2±14.3    \<0.001   \<0.001
   FVC L                                       2.88±1.13                  2.69±1.01              3.11±1.41         3.14±1.06        2.24±1.00        2.75±0.60      3.85±1.00    \<0.001   \<0.001
   FVC % pred                                  77.9±21.1                  73.7±20.2              91.5±2.2          85.0±16.0        67.2±11.9        75.5±16.2      96.7±11.9    \<0.001   \<0.001
   FEV~1~/FVC ratio^+^                         62.9±15.9                  59.7±15.3              57.5±10.9         65.6±10.4        56.9±18.1        48.7±13.5       79.7±6.9    \<0.001   \<0.001
   RV L                                        3.68±1.57                  3.92±1.57              3.76±1.40         2.97±0.87        3.58±1.20        4.28±1.15      2.51±0.91    \<0.001   \<0.001
   RV % pred                                   163.9±68.5                174.8±69.2             166.1±50.4         132.8±40.7      141.7±23.5        182.7±39.9     111.3±34.8   \<0.001   \<0.001
   *R*~TOT~ kPa·s·L^−1^                        0.43±0.28                  0.47±0.29              0.34±0.14         0.34±0.18        0.46±0.08        0.63±0.33      0.23±0.10    \<0.001   \<0.001
   *R*~TOT~ % pred                             143.1±95.2                156.9±98.2             113.9±47.9         113.5±60.8      153.6±27.3       213.3±113.9     77.2±32.6    \<0.001   \<0.001
   *D*~LCO~ % pred                             55.8±19.6                  48.5±16.0              74.9±8.2          53.9±11.4        47.7±15.3        36.3±15.2      77.1±13.4    \<0.001   \<0.001
   *D*~LCO~/*V*~A~ % pred                      67.8±24.2                  60.5±22.0              88.2±7.1          69.4±16.1        70.2±18.5        47.5±18.2      90.7±15.7    \<0.001   \<0.001
  **Capillary blood gas analysis**                                                                                                                                                        
   *P*~O~2~~ mmHg                              68.1±12.3                  66.2±12.6              70.1±5.6           64.6±8.5        64.0±3.0          61.2±8.0       77.0±5.7     0.001    \<0.001
   *P*~CO~2~~ mmHg                              36.0±6.5                  36.2±6.8               33.5±6.2           34.4±7.3        37.4±0.8          38.1±4.8       35.0±4.6     0.16      0.42
   *S*~O~2~~ %                                  94.0±2.9                  93.6±3.0               95.7±0.7           93.9±3.3        94.0±2.0          91.8±2.9       96.0±1.2    \<0.001   \<0.001

Data are presented as n or mean±[sd]{.smallcaps}, unless otherwise stated. COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; *R*~TOT~: total resistance; *D*~LCO~: diffusion capacity of the lung for carbon monoxide; *V*~A~: alveolar volume; *P*~O~2~~: oxygen tension; *P*~CO~2~~: carbon dioxide tension; *S*~O~2~~: oxygen saturation. ^\#^: intercohortal comparison was performed by defining controls as the COPD GOLD 0 group, p-values refer to data comparison between all five groups (COPD GOLD 0 through D); ^¶^: p-values refer to data comparison between the entire COPD group and controls; ^+^: based on post-bronchodilator FEV~1~.

Among current or former control smokers, pulmonary function testing excluded presence of COPD: FEV~1~/FVC ratio was 79.7±6.9% and FEV~1~ was 98.2±14.3% of predicted, although quantitative smoking history was balanced between controls and COPD patients (p=0.54).

Angiological results {#s3b}
--------------------

Angiological testing identified LEAD to be present in 86 out of 107 patients (80.4% of the COPD study population): 57.0% were found to be in Fontaine stage I, 12.2% in Fontaine stage IIA, 10.3% in Fontaine stage IIB and 0.9% in Fontaine stage III. Among controls, 12 out of 22 subjects (*i.e.* 54.5% of the control cohort) were in Fontaine stage I, whereas no higher LEAD grade was ascertained. Thus, as compared with controls, LEAD frequency was significantly higher among COPD patients (80.4% *versus* 54.5%, p=0.002). In order to evaluate the association between GOLD severity and LEAD Fontaine stages, univariate analysis demonstrated a significant increase of LEAD stages over GOLD classes (p\<0.001). Statistical significance was persistently upheld after combination of GOLD stages A and B as well as stages C and D into two categorical variables, given the limited number of patients in the less symptomatic GOLD stages A and C (p=0.003) ([figure 1](#F1){ref-type="fig"}). *Vice versa*, FEV~1~ decreased significantly over LEAD stages (p\<0.001) ([figure 2](#F2){ref-type="fig"}).

![Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups A/B and C/D (p=0.003).](00037-2016.01){#F1}

![Forced expiratory volume in 1 s (FEV~1~) % pred stratified by lower extremity artery disease (LEAD) Fontaine stages (p\<0.001).](00037-2016.02){#F2}

Pulse volume recording ascertained bilaterally concordant PWI values (Pearson\'s r=0.75, p\<0.001); PWI was impaired significantly within COPD severity groups (p=0.007). cPWV was 7.21±3.62 m·s^−1^ and did not manifest significant distributive changes neither over COPD stages nor by comparison of COPD patients with controls.

Although controls were not free from carotid artery atherosclerosis, as 36.4% had nonstenotic plaque in the common or internal carotid arteries, the frequency of carotid artery disease increased to 58.9% in COPD patients (p=0.003) and was accompanied by a significant increase in plaque load over COPD GOLD stages (p=0.04).

In the entire study population (n=129), statistically significant relations were observed on linear regression analysis between COPD GOLD groups and FEV~1~ % pred, on the one hand, and presence of plaque and stenosis in lower extremity arteries, plaque burden in carotid arteries, PWI, ABI, and leukocyte count, on the other hand ([table 3](#TB3){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). Concurrently, leukocyte count was significantly related to hs-CRP (Pearson\'s r=0.25, p=0.01) and pulmonary testing parameters indicating obstructive airflow limitation (FEV~1~ % pred: Pearson\'s r= −0.31, p=0.001; FEV~1~/FVC ratio: Pearson\'s r= −0.23, p=0.01).

###### 

Correlation analysis between pulmonary, angiological and laboratory parameters in the study population

                                       **COPD GOLD stage**   **FEV**~1~ **% pred**   **RV % pred**                      
  ------------------------------------ --------------------- ----------------------- --------------- --------- -------- -------
  **Lower extremity artery disease**                                                                                    
   Fontaine stage                      0.413                 \<0.001                 −0.433          \<0.001   0.230    0.02
   Plaque burden                       0.373                 \<0.001                 −0.371          \<0.001   0.182    0.05
   Stenosis                            0.291                 0.002                   −0.326          \<0.001   0.230    0.01
   ABI (mean)                          −0.385                \<0.001                 0.386           \<0.001   −0.224   0.01
   PWI (mean)                          0.258                 0.007                   −0.249          0.01      0.091    0.357
   cPWV                                0.135                 0.211                   −0.162          0.13      0.120    0.27
  **Carotid artery disease**                                                                                            
   Plaque burden                       0.184                 0.04                    −0.216          0.02      0.040    0.68
  **Laboratory parameters**                                                                                             
   Total leukocyte count               0.242                 0.008                   −0.312          0.001     0.180    0.05
   hs-CRP                              0.033                 0.73                    −0.014          0.89      0.051    0.60

COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV~1~: forced expiratory volume in 1 s; RV: residual volume; ABI: ankle--brachial index; PWI: pulse wave index; cPWV: central pulse wave velocity; hs-CRP: high-sensitivity C-reactive protein. Intercohortal comparison was performed by defining controls as COPD GOLD 0 group, p-values refer to data comparison between all five groups (COPD GOLD 0 through D). Pulmonary function parameters are based on post-bronchodilator measurement.

![Linear regression analysis between a) forced expiratory volume in 1 s (FEV~1~) % pred and ankle--brachial index (ABI), b) residual volume (RV) % pred and ABI, and c) FEV~1~ % pred and pulse wave index (PWI). Individual data points are presented; the solid and dashed lines indicate the mean and 95% prediction intervals, respectively.](00037-2016.03){#F3}

A stepwise multiple logistic regression analysis was used to further investigate the association between presence of plaque in lower extremity arteries and established LEAD risk factors (age, gender, pack-years of smoking, arterial hypertension, diabetes mellitus, hyperlipidaemia and familial disposition). The only cardiovascular risk factor identified to be independently associated with plaque presence was age (odds ratio (OR) 1.05, 95% CI 1.00--1.10, p=0.039). Overall, COPD GOLD status was the strongest independent predictor for presence of plaque both in lower extremity arteries (OR 1.63, 95% CI 1.19--2.25, p=0.003) and carotids (OR 1.66, 95% CI 1.14--2.44, p=0.009).

Discussion {#s4}
==========

The present study conducted on a heterogeneous COPD population of considerable size demonstrates an unexpectedly high LEAD frequency of 80.4% that substantially exceeds the frequency ascertained in our matched control smokers without COPD. Both LEAD severity degrees and PWI manifested a significant increase with the degree of obstructive airflow limitation, whereas ABI values decreased. In terms of carotid artery disease, carotid plaque burden exhibited significant distributive differences over FEV~1~ % pred. As a marker of systemic inflammation, total leukocyte count was related to both COPD and LEAD severity degrees.

Although the traditional diagnostic and therapeutic focus of COPD had rested on the presence and management of chronic airflow limitation, COPD has now been recognised as a systemic disorder whose course is substantially influenced by its comorbid conditions \[[@C4]\]. According to mortality statistics and large-scale clinical COPD trials \[[@C14], [@C15]\], 25--50% of mortality is attributable to cardiovascular comorbidities that thereby constitute a major cause of death in COPD. It is conceivable that the elevated cardiovascular morbidity and mortality arise from the common stressors, such as smoking and arterial hypertension, that COPD patients are subjected to. However, a growing body of evidence has associated reduced FEV~1~ *per se* with cardiovascular risk, irrespective of conventional cardiovascular risk stratifiers \[[@C16]\]. Whereas the concomitance of coronary heart disease and COPD has repeatedly been the focus of research \[[@C17], [@C18]\], the prevalence and mutual interaction of peripheral vascular disease in COPD remain less well defined. In a cohort of 30 patients with advanced LEAD according to at least Fontaine stage IIB, spirometry identified concomitant COPD in 14 cases \[[@C8]\]. *Vice versa*, in a Spanish cross-sectional COPD study, P[ecci]{.smallcaps} *et al*. \[[@C19]\] ascertained abnormal ABI values in 36.8% of COPD patients, of whom approximately 70% showed asymptomatic LEAD. Likewise, cross-sectional evidence that LEAD did not impaired over COPD severity stages was provided by W[atz]{.smallcaps} *et al.* \[[@C20]\]. Contrary to our results and broadly in line with the observations made by P[ecci]{.smallcaps} *et al*. \[[@C19]\], W[atz]{.smallcaps} *et al.* \[[@C20]\] assessed a LEAD frequency of only 25.3% among COPD patients. These discrepant LEAD frequency data are mainly due to a different methodology: in both aforementioned studies LEAD diagnosis relied solely on ABI measurement and therein differed significantly from our angiological approach. We complemented ABI measurement by additional colour-coded duplex sonography for visualisation of the extent and severity of vascular lesions. Thereby, we found lower extremity artery plaque load to be significantly associated with the severity of obstructive airflow limitation (p\<0.001) ([table 3](#TB3){ref-type="table"}). Complementary pulse wave analysis permitted quantification of PWI that was likewise inversely associated with FEV~1~ % pred (p=0.01) ([figure 3c](#F3){ref-type="fig"}).

When considering sole ABI measurement, the percentages of ABI values that indicate a mild (ABI 0.7 to \<0.9), moderate (ABI 0.5 to \<0.7) and severe peripheral circulatory compromise (ABI \<0.5) averaged 24.3%, 12.1% and 5.6%, respectively, within our COPD cohort. Among controls, only 13.6% exhibited an ABI of 0.7 to \<0.9, whereas the remaining controls (86.4%) presented nonpathological ABI values. These data on LEAD frequency are largely consistent with the prevalence reported by S[igvant]{.smallcaps} *et al.* \[[@C21]\]: in this Swedish population-based point-prevalence study, LEAD was diagnosed based on ABI in 18% of subjects. The fact that the final LEAD frequency among our controls increased to 54.5% supports the advantages of the presently employed additional angiological screening methods.

In the current study, we identified age to be the only cardiovascular risk factor that was independently associated with plaque presence in lower extremity arteries. Epidemiological data on LEAD show that its frequency is strongly age-related \[[@C22]\]. Its superiority over other common risk factors is due to the fact that it serves as a marker for the duration of exposure to other cardiovascular risk factors \[[@C23]\]. In keeping with this and on the basis of our study results, the elderly COPD patients in particular appear to be exposed to the risk of developing atherosclerotic lesions and should be directed to preventive angiological testing.

A significant relation between arterial compliance and pulmonary emphysema severity has been reported by M[c]{.smallcaps}A[llister]{.smallcaps} *et al.* \[[@C24]\]. Likewise, we presently observed interdependency between the plethysmographically assessed residual volume and LEAD Fontaine stages (p=0.02). Thus, there is mounting evidence that suggests a persistent, largely hypoxia-mediated low-grade systemic inflammation in COPD that enhances endothelial dysfunction as a direct precursor of atherosclerosis \[[@C25]\]. The inflammatory cascade that initially arises from exposure to noxious substances, mainly tobacco smoke, accelerates atherogenesis at all stages by formation, destabilisation and rupture of plaque as well as by platelet activation and clotting that lead to atheroma formation and atherothrombosis \[[@C2], [@C26]\]. In line with the assumption that systemic inflammation may link systemic vascular function to COPD status, we show that total leukocyte count is associated with both COPD and LEAD stages, and positively correlated with hs-CRP levels. hs-CRP, in turn, was significantly linked to PWI as well as to the presence and severity of carotid artery disease.

In terms of carotid artery disease, we identified carotid plaque to be significantly more prevalent in COPD patients than in control subjects, to manifest a significant increase over COPD GOLD stages and to be related to inflammation markers (leukocytes, hs-CRP). These observations are in line with the results obtained by L[ahousse]{.smallcaps} *et al.* \[[@C27]\] who addressed the question why COPD patients are prone to ischaemic stroke and why the risk of stroke-associated mortality increases with the degree of airflow limitation. In their population-based cohort study, ultrasonography revealed a twofold increased risk of carotid artery plaque formation among COPD patients as compared with controls. Additional high-resolution carotid magnetic resonance imaging scanning showed a significantly higher presence of lipid core plaque as an indicator of plaque vulnerability. Both carotid artery wall thickening and lipid core plaque formation correlated with severity of airflow limitation \[[@C27]\].

There are several limitations to be considered. First, we assume that selection and procedure bias might have arisen from our single-centre, cross-sectional study design. However, we did not intend to establish causality between both disease entities, but aimed at providing an accurate estimation of the frequency of peripheral artery disease in COPD. Thus, assessment of a broader range of inflammatory biomarkers beyond total leukocyte count and hs-CRP would have been a valuable adjunct to define the linkage between systemic vascular function and COPD status. Secondly, although all COPD GOLD stages were present in our study, the number of GOLD A and C stage patients was restricted as a consequence of the study enrolment process: as patients were recruited at the University Hospital\'s Dept of Pneumology, less symptomatic patients (*i.e.* those in GOLD stages A and C) were under-represented. To overcome this limitation, we additionally combined GOLD A and B as well as GOLD C and D into two categorical variables for comparison of their respective angiological results. Moreover, we focused on FEV~1~ as a marker for obstructive airflow limitation rather than on COPD severity stages *per se*. Finally, a larger control cohort would have conferred additional comparative value to our findings. However, control enrolment was afflicted by a high number of undiagnosed COPD cases in presumably lung-healthy current or former smokers.

Conclusions {#s4a}
-----------

LEAD and carotid artery disease were diagnosed in an unexpectedly sizeable proportion of COPD patients as compared with control subjects. Reduced lung function and pulmonary hyperinflation were directly related to peripheral circulatory compromise. In view of the complexity of both COPD and peripheral arterial disease, the underlying pathophysiological linkage is multifactorial; yet, systemic inflammatory processes appear to be major contributing factors. These observations raise the question as to what extent effective COPD management would be advantageous with regard to onset and progress of peripheral arterial disease.
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